Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Diagnostics Raises $1.8M

NEW YORK (GenomeWeb News) – Precipio Diagnostics has raised $1.8 million in a Series B financing round, Connecticut Innovations, the lead investor in the round, said today.

Along with CI, which invested $750,000 in the round through its Eli Whitney Fund, Ironwood Capital, Enhanced Capital, Kuzari Capital, and individual investors participated in the financing.

Based in New Haven, Conn., Precipio provides pathology services, with a focus on cancer diagnostics. It began operations about a year-and-a-half ago and has exclusive deals with Yale School of Medicine and Yale-New Haven Hospital to analyze patients samples and report on their findings. It also licenses technologies from Yale that include a tumor profiling test suite and a prognostic biomarker for ovarian cancer.

Among the tests offered by Precipio are those based on PCR, cytogenetics, fluorescent in situ hybridization, and other technologies.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.